, Volume 106, Supplement 1, pp S56–S61

Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline


  • H. Allain
    • Experimental and Clinical Pharmacology LaboratoryFaculty of Medicine
  • A. Lieury
    • Experimental Psychology LaboratoryUniversity of Haute Bretagne
  • F. Brunet-Bourgin
    • Technopole Atalante
  • C. Mirabaud
    • Roche Products
  • P. Trebon
    • Technopole Atalante
  • F. Le Coz
    • Technopole Atalante
  • J. M. Gandon
    • Technopole Atalante
Section II Psychomotor Performance And Cognitive Performance

DOI: 10.1007/BF02246237

Cite this article as:
Allain, H., Lieury, A., Brunet-Bourgin, F. et al. Psychopharmacology (1992) 106: S56. doi:10.1007/BF02246237


The respective effects of three antidepressant drugs (moclobemide, 450 mg/j; viloxazine, 300 mg/j; maprotiline, 150 mg/j) on vigilance, attention, and memory were compared. Young depressed outpatients (n=46) entered a double-blind, randomised, monocentre clinical trial lasting for 6 weeks. Drug actions were assessed through the regular determination of critical flicker fusion point (CFF), reaction times (SRT), and a battery to measure memory components. None of the three drugs caused deterioration in cognitive functions. On the other hand, moclobemide improved both vigilance and attention (CFF, SRT) and some crucial components of memory (general memory scores, delayed word recall, recognition of familiar faces). This effect was rapid, stable, and superior to those of viloxazine and maprotiline. It may be explained by moclobemide's selective and reversible inhibition of monoamine oxidase A, as well as by the lack of any anticholinergic action.

Key words


Copyright information

© Springer-Verlag 1992